After GW Pharmaceuticals reported positive data in a Phase 3 trial involving Lennox-Gastaut Syndrome, or :LGS,patients, Janney Capital says that the data does not lessen its "many concerns" about the company. The firm says that the :LGS data was "good but not great" compared with competing drugs, and it's worried about drug interactions between GW's Epidiolex and other antiepileptic drugs. The firm says that Epidiolex's efficacy is good enough to be approved, but not strong enough to justify high adoption at premium prices. Moreover, it says that the stock's valuation is worrisome at current levels, and it keeps a Sell rating on the shares.